Izana starts midstage trial of spinal arthritis drug by Phil Taylor Monday, August 13, 2018 Brand-new U.K. biotech Izana has kicked off a phase 2a trial of anti-GM-CSF antibody namilumab in ankylosing spondylitis.
Liver-focused Ambys launches with $140M, Takeda partnership by Amirah Al Idrus Wednesday, August 8, 2018 Ambys Medicines will develop cell and gene therapies, as well as drugs, for chronic liver diseases.
After its recent funding round, HiFiBiO pens Takeda R&D collab by Ben Adams Monday, July 30, 2018 HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda to work on antibody therapies.
Ovid, Takeda add 2 rare epilepsies to rare drug pact by Amirah Al Idrus Wednesday, July 18, 2018 The pair will start three new trials in the third quarter, including a phase 2 pilot study in CDKL5 deficiency disorder and duplication 15q syndrome.
Celgene, Takeda invest in intratumoral microdosing firm Presage by Nick Paul Taylor Tuesday, July 17, 2018 Presage has an intratumoral microdosing platform designed to quickly evaluate how experimental solid tumor therapies perform in humans.
Dementia Discovery Fund reels in $350M for disease-modifying drugs by Amirah Al Idrus Monday, June 25, 2018 The Dementia Discovery Fund capped its fundraising at $350 million; it was nudged across the line by a $60 million investment from AARP.
Organ-chip developer Emulate raises $36M in VC funding by Conor Hale Tuesday, June 19, 2018 Organ-chip developer Emulate gathered $36 million in VC financing and plans to include a wider range of diseases in its models for drug testing.
Ex-Takeda exec takes up CMO post at CD47 biotech Trillium by Nick Paul Taylor Thursday, June 7, 2018 Yaping Shou, M.D., Ph.D., joins the anti-CD7 cancer biotech from Takeda’s oncology department, where she worked as executive medical director.
Gilead, Hookipa pen hepatitis B, HIV research collaboration by Nick Paul Taylor Wednesday, June 6, 2018 Gilead is committing to milestones that could exceed $400 million to snag exclusive rights to two technologies in the indications.
Takeda divests Chinese JV for $280M by Amirah Al Idrus Tuesday, May 22, 2018 Takeda's $62 billion acquisition of Shire added $31 billion to its debt load. Now, it's looking to cut costs where it can.
